[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2018008514A - Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones cancerosas. - Google Patents

Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones cancerosas.

Info

Publication number
MX2018008514A
MX2018008514A MX2018008514A MX2018008514A MX2018008514A MX 2018008514 A MX2018008514 A MX 2018008514A MX 2018008514 A MX2018008514 A MX 2018008514A MX 2018008514 A MX2018008514 A MX 2018008514A MX 2018008514 A MX2018008514 A MX 2018008514A
Authority
MX
Mexico
Prior art keywords
compositions
methods related
cancerose
indications
cell systems
Prior art date
Application number
MX2018008514A
Other languages
English (en)
Inventor
B Afeyan Noubar
J Deans Robert
Mata-Fink Jordi
Round John
Kahvejian Avak
F Chen Tiffany
Straight Nissen Torben
Dowden Nathan
Wickham Tom
Elloul Sivan
Original Assignee
Rubius Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubius Therapeutics Inc filed Critical Rubius Therapeutics Inc
Publication of MX2018008514A publication Critical patent/MX2018008514A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención incluye composiciones y métodos relacionados con terapias multimodales, por ejemplo, para tratar un cáncer. Una terapia multimodal descrita en la presente proporciona y/o administra una pluralidad de agentes que actúan de manera coordinada para proporcionar un beneficio terapéutico a un sujeto que la necesite, por ejemplo, un sujeto que padece un cáncer.
MX2018008514A 2016-01-11 2017-01-11 Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones cancerosas. MX2018008514A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662277130P 2016-01-11 2016-01-11
US201662359448P 2016-07-07 2016-07-07
US201662370915P 2016-08-04 2016-08-04
US201662420973P 2016-11-11 2016-11-11
PCT/US2017/013035 WO2017123646A1 (en) 2016-01-11 2017-01-11 Compositions and methods related to multimodal therapeutic cell systems for cancer indications

Publications (1)

Publication Number Publication Date
MX2018008514A true MX2018008514A (es) 2019-05-09

Family

ID=57907000

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018008514A MX2018008514A (es) 2016-01-11 2017-01-11 Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones cancerosas.
MX2018008515A MX2018008515A (es) 2016-01-11 2017-01-11 Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones inmunitarias.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018008515A MX2018008515A (es) 2016-01-11 2017-01-11 Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones inmunitarias.

Country Status (22)

Country Link
US (8) US10456421B2 (es)
EP (3) EP3402492B1 (es)
JP (5) JP2019501655A (es)
KR (2) KR20180095098A (es)
CN (3) CN108697733A (es)
AU (2) AU2017207738A1 (es)
BR (2) BR112018013853A2 (es)
CA (2) CA3010510A1 (es)
DK (1) DK3402491T3 (es)
ES (1) ES2907695T3 (es)
HK (1) HK1259079A1 (es)
HR (1) HRP20220147T1 (es)
HU (1) HUE057660T2 (es)
IL (2) IL259991A (es)
LT (1) LT3402491T (es)
MX (2) MX2018008514A (es)
PL (1) PL3402491T3 (es)
PT (1) PT3402491T (es)
RS (1) RS62939B1 (es)
SG (4) SG11201805442XA (es)
SI (1) SI3402491T1 (es)
WO (2) WO2017123644A1 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2768942B1 (en) 2011-10-17 2019-12-04 Massachusetts Institute of Technology Intracellular delivery
KR102530914B1 (ko) 2013-08-16 2023-05-11 메사추세츠 인스티튜트 오브 테크놀로지 세포로의 선택적 물질 전달
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
MX2020000621A (es) 2014-04-01 2020-11-12 Rubius Therapeutics Inc Composiciones para usarse en inmunomodulacion.
SG11201703044PA (en) 2014-10-31 2017-05-30 Massachusetts Inst Technology Delivery of biomolecules to immune cells
CN107002089B (zh) 2014-11-14 2021-09-07 麻省理工学院 化合物和组合物向细胞中的破坏和场实现的递送
JP7278027B2 (ja) 2015-01-12 2023-05-19 マサチューセッツ インスティテュート オブ テクノロジー マイクロ流体送達による遺伝子編集
WO2017008063A1 (en) 2015-07-09 2017-01-12 Massachusetts Institute Of Technology Delivery of materials to anucleate cells
US11613759B2 (en) 2015-09-04 2023-03-28 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
MX2018008514A (es) 2016-01-11 2019-05-09 Rubius Therapeutics Inc Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones cancerosas.
EP3583202A1 (en) * 2017-02-17 2019-12-25 Rubius Therapeutics, Inc. Functionalized erythroid cells
US20210228738A1 (en) * 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
US10960071B2 (en) 2017-08-07 2021-03-30 The Regents Of The University Of California Platform for generating safe cell therapeutics
AU2018328283A1 (en) * 2017-09-07 2020-02-20 Cue Biopharma, Inc. Antigen-presenting polypeptides and methods of use thereof
CN111655292A (zh) * 2017-12-07 2020-09-11 旗舰先锋创新V股份有限公司 细胞生物制品及其治疗用途
CN111712254A (zh) * 2017-12-23 2020-09-25 鲁比厄斯治疗法股份有限公司 人工抗原呈递细胞和使用方法
MX2020009359A (es) 2018-03-08 2021-01-29 Rubius Therapeutics Inc Sistemas de celulas terapeuticas y metodos para el tratamiento de cancer y enfermedades infecciosas.
EP3774926A1 (en) 2018-04-05 2021-02-17 Bio-Rad ABD Serotec GmbH Display systems for proteins of interest
WO2019226922A1 (en) * 2018-05-24 2019-11-28 Rush University Medical Center Icosl for use as a renal therapeutic
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
KR20210151049A (ko) 2019-01-18 2021-12-13 플래그쉽 파이어니어링, 인크. Trem 조성물 및 이의 용도
SG11202109073VA (en) * 2019-02-20 2021-09-29 Rubius Therapeutics Inc Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use
US20220143062A1 (en) 2019-03-04 2022-05-12 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides and pharmaceutical compositions thereof
WO2020188356A1 (en) * 2019-03-18 2020-09-24 Bio-Rad Abd Serotec Gmbh Antigen binding fragments conjugated to a plurality of fc isotypes and subclasses
EP3946466A2 (en) 2019-03-25 2022-02-09 Flagship Pioneering Innovations VI, LLC Compositions comprising modified circular polyribonucleotides and uses thereof
WO2020223657A1 (en) * 2019-05-02 2020-11-05 Predictive Technology Group, Inc. Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk
CN114269921A (zh) 2019-05-31 2022-04-01 旗舰创业股份有限公司 TREM组合物用以调节tRNA池的用途
AU2020292427A1 (en) 2019-06-14 2022-01-06 Flagship Pioneering Innovations Vi, Llc Circular RNAs for cellular therapy
US20220305128A1 (en) 2019-06-19 2022-09-29 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
CN112195154B (zh) * 2019-07-08 2024-03-29 江苏汇智生物科技有限公司 一种基因改造表达改造型pla2r受体的细胞及其应用
WO2021046424A2 (en) 2019-09-05 2021-03-11 Hemanext Inc. Methods for the preservation of reagent red blood cells using carbon monoxide
WO2021073613A1 (en) * 2019-10-18 2021-04-22 Westlake Therapeutics (Hangzhou) Co. Limited Engineered red blood cells presenting specific cancer neoantigen with artificial mhc
EP4055169A1 (en) 2019-11-04 2022-09-14 Flagship Pioneering, Inc. Methods of modifying a nucleic acid sequence
WO2021092064A1 (en) 2019-11-04 2021-05-14 Flagship Pioneering, Inc. Trem compositions for con-rare codons and related uses
US20230340451A1 (en) 2020-01-29 2023-10-26 Flagship Pioneering Innovations Vi, Llc Compositions comprising linear polyribonucleotides for protein modulation and uses thereof
TW202142689A (zh) 2020-01-29 2021-11-16 美商旗艦先鋒創新有限責任公司 用於轉譯之組合物及其使用方法
WO2021155171A1 (en) 2020-01-29 2021-08-05 Flagship Pioneering Innovations Vi, Llc Delivery of compositions comprising circular polyribonucleotides
CA3169984A1 (en) * 2020-02-07 2021-08-12 The Regents Of The University Of California Methods and use for bioengineering enucleated cells
WO2021236952A1 (en) 2020-05-20 2021-11-25 Flagship Pioneering, Inc. Compositions and methods for producing human polyclonal antibodies
IL298363A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
CN116322760A (zh) 2020-05-20 2023-06-23 旗舰创业创新第六有限责任公司 冠状病毒抗原组合物及其用途
US20230203510A1 (en) 2020-05-29 2023-06-29 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods relating thereto
EP4158032A2 (en) 2020-05-29 2023-04-05 Flagship Pioneering Innovations VI, LLC Trem compositions and methods relating thereto
US20230233514A1 (en) 2020-06-23 2023-07-27 Flagship Pioneering, Inc. Antiviral compounds and methods of using the same
IL300947A (en) 2020-09-03 2023-04-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
AU2021409740A1 (en) 2020-12-23 2023-07-06 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
TW202241471A (zh) 2021-01-08 2022-11-01 美商盧比亞斯治療公司 提高個體中NKp30陽性淋巴球的方法及其用途
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
JP2024508456A (ja) * 2021-02-26 2024-02-27 サイトナス セラピューティクス，インク． 治療的送達のための組成物および方法
WO2022197548A1 (en) 2021-03-14 2022-09-22 Rubius Therapeutics, Inc. Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2023009547A1 (en) 2021-07-26 2023-02-02 Flagship Pioneering Innovations Vi, Llc Trem compositions and uses thereof
JP2024534428A (ja) 2021-09-17 2024-09-20 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 環状ポリリボヌクレオチドを生成するための組成物及び方法
JP2024538062A (ja) * 2021-10-12 2024-10-18 サイトナス セラピューティクス，インク． 治療用細胞の製造のためのシステムおよび方法
TW202322826A (zh) 2021-10-18 2023-06-16 美商旗艦先鋒創新有限責任公司 用於純化多核糖核苷酸之組成物及方法
JP2024541465A (ja) 2021-11-24 2024-11-08 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー 免疫原性組成物及びその使用
MX2024006407A (es) 2021-11-24 2024-08-19 Flagship Pioneering Innovations Vi Llc Composiciones de inmunogenos del virus varicela-zoster y sus usos.
CA3239266A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Coronavirus immunogen compositions and their uses
CA3241061A1 (en) 2021-12-22 2023-06-29 Alexandra Sophie DE BOER Compositions and methods for purifying polyribonucleotides
IL313714A (en) 2021-12-23 2024-08-01 Flagship Pioneering Innovations Vi Llc Cyclic polyribonucleotides encoding antifusogenic polypeptides
AU2023269030A1 (en) 2022-05-09 2024-11-14 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
TW202409283A (zh) 2022-05-13 2024-03-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 雙股ｄｎａ組合物及相關方法
WO2023230566A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating cytokines
WO2023230549A2 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of tumor suppressors and oncogenes
AU2023276714A1 (en) 2022-05-25 2024-11-21 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulation of immune responses
AU2023276715A1 (en) 2022-05-25 2025-01-09 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating circulating factors
AU2023277636A1 (en) 2022-05-25 2024-11-21 Flagship Pioneering Innovations Vii, Llc Compositions and methods for modulating genetic drivers
WO2023250112A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
WO2024059740A1 (en) * 2022-09-14 2024-03-21 Synthego Corporation Genetically modified polynucleotides and cells expressing modified mhc proteins and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024097664A1 (en) 2022-10-31 2024-05-10 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
TW202434728A (zh) 2022-11-08 2024-09-01 美商旗艦先鋒創新有限責任公司 用於產生環狀多核糖核苷酸的組成物和方法
WO2024129988A1 (en) 2022-12-14 2024-06-20 Flagship Pioneering Innovations Vii, Llc Compositions and methods for delivery of therapeutic agents to bone
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
US20240252520A1 (en) 2023-01-09 2024-08-01 Beth Israel Deaconess Medical Center, Inc. Therapeutic agents and their use for treating chronic wounds
US20240238473A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
TW202438089A (zh) 2023-02-17 2024-10-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 包含經修飾的尿嘧啶的ｄｎａ組成物
US20240293582A1 (en) 2023-02-17 2024-09-05 Flagship Pioneering Innovations Vii, Llc Dna compositions comprising modified cytosine
WO2024192420A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Compositions comprising polyribonucleotides and uses thereof
WO2024192422A1 (en) 2023-03-15 2024-09-19 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
WO2024215879A1 (en) * 2023-04-12 2024-10-17 Cytonus Therapeutics, Inc. Manufacturing systems and methods for cellular therapeutic platforms
WO2024216128A1 (en) 2023-04-12 2024-10-17 Flagship Pioneering Innovations Vi, Llc Trems for use in correction of missense mutations
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026290A1 (en) * 1993-05-07 1994-11-24 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
CA2293632C (en) 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US20020151004A1 (en) * 2000-07-24 2002-10-17 Roger Craig Delivery vehicles and methods for using the same
CA2418835A1 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
WO2004087876A2 (en) * 2003-03-25 2004-10-14 Valeocyte Therapies Llc Use of red blood cells to facilitate cell activation
DE10335833A1 (de) * 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
FR2873925B1 (fr) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
FR2884717B1 (fr) 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
PL1899364T5 (pl) 2005-05-17 2024-12-09 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
WO2007030708A2 (en) 2005-09-08 2007-03-15 Adnexus Therapeutics, Inc. Antimicrobial adzymes and uses thereof
US7462485B2 (en) 2005-10-07 2008-12-09 Glaser Lawrence F Modified erythrocytes and uses thereof
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
FR2925339B1 (fr) 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas
ES2405258T3 (es) 2008-02-13 2013-05-30 Erytech Pharma Formulación y procedimiento para la prevención y el tratamiento de la manifestación esquelética de la enfermedad de Gaucher
FR2928270B1 (fr) 2008-03-10 2011-01-21 Erytech Pharma Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
US8211656B2 (en) * 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
FR2938332B1 (fr) 2008-11-07 2011-11-25 Erytech Pharma Test predictif de la neutralisation de l'activite asparaginase
FR2944106B1 (fr) 2009-04-03 2012-09-28 Erytech Pharma Methode de dosage de l'inositol hexaphosphate (ihp).
RU2012121865A (ru) 2009-10-27 2013-12-10 Эритек Фарма Композиция для индуцирования специфической иммунологической толерантности
AU2011289579B2 (en) * 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US20150118265A1 (en) 2012-03-13 2015-04-30 Anthrogenesis Corporation Modified erythrocyte precursor cells and uses thereof
RU2667639C2 (ru) 2012-03-21 2018-09-21 Эритек Фарма Лекарственное средство для лечения острого миелоидного лейкоза (омл)
CN103224957B (zh) 2013-04-16 2017-08-04 福建三一造血技术有限公司 体外诱导生成含L‑ASPase II的红细胞药物的方法
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
JP6603209B2 (ja) 2013-05-10 2019-11-06 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾
EP3693398A1 (en) 2013-05-10 2020-08-12 Whitehead Institute for Biomedical Research In vitro production of red blood cells with sortaggable proteins
EP2813234A1 (en) 2013-06-11 2014-12-17 Erytech Pharma Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
MX2020000621A (es) 2014-04-01 2020-11-12 Rubius Therapeutics Inc Composiciones para usarse en inmunomodulacion.
WO2016183482A1 (en) * 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
EP3187190A1 (en) 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
MX2018008514A (es) 2016-01-11 2019-05-09 Rubius Therapeutics Inc Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones cancerosas.
US20190161730A1 (en) 2016-07-07 2019-05-30 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems expressing exogenous rna
KR20190091497A (ko) 2016-12-02 2019-08-06 루비우스 테라퓨틱스, 아이엔씨. 고형 종양으로의 침투를 위한 세포 시스템과 관련된 조성물 및 방법
EP3583202A1 (en) 2017-02-17 2019-12-25 Rubius Therapeutics, Inc. Functionalized erythroid cells
EP3672602A1 (en) 2017-08-22 2020-07-01 Rubius Therapeutics, Inc. Lipid nanoparticle methods and compositions for producing engineered erythroid cells
WO2019090148A2 (en) 2017-11-03 2019-05-09 Rubius Therapeutics, Inc. Compositions and methods related to therapeutic cell systems for tumor growth inhibition
US20190201548A1 (en) 2017-12-29 2019-07-04 Rubius Therapeutics, Inc. Gene editing and targeted transcriptional modulation for engineering erythroid cells

Also Published As

Publication number Publication date
JP2021078519A (ja) 2021-05-27
JP2022171843A (ja) 2022-11-11
CN115969987A (zh) 2023-04-18
SG11201805442XA (en) 2018-07-30
EP3402492A1 (en) 2018-11-21
US20190083540A1 (en) 2019-03-21
PL3402491T3 (pl) 2022-04-19
US20220072048A1 (en) 2022-03-10
US20230293588A1 (en) 2023-09-21
US10568910B2 (en) 2020-02-25
US10716811B2 (en) 2020-07-21
US20180187155A1 (en) 2018-07-05
CN108697733A (zh) 2018-10-23
US20200016209A1 (en) 2020-01-16
AU2017207738A1 (en) 2018-07-12
US20200129556A1 (en) 2020-04-30
KR20180095098A (ko) 2018-08-24
CN108778298A (zh) 2018-11-09
HK1259079A1 (zh) 2019-11-22
HUE057660T2 (hu) 2022-06-28
JP7093302B2 (ja) 2022-06-29
US10456421B2 (en) 2019-10-29
SG10202007639SA (en) 2020-09-29
MX2018008515A (es) 2019-05-09
US20180085402A1 (en) 2018-03-29
WO2017123644A1 (en) 2017-07-20
BR112018013728A2 (pt) 2018-12-18
BR112018013853A2 (pt) 2018-12-18
IL259991A (en) 2018-07-31
US10517897B1 (en) 2019-12-31
CA3010510A1 (en) 2017-07-20
JP2019501654A (ja) 2019-01-24
ES2907695T3 (es) 2022-04-26
SI3402491T1 (sl) 2022-05-31
KR20180095713A (ko) 2018-08-27
JP2021112216A (ja) 2021-08-05
WO2017123646A1 (en) 2017-07-20
EP3402492B1 (en) 2022-11-16
DK3402491T3 (da) 2022-02-14
US20180193385A1 (en) 2018-07-12
EP3402491A1 (en) 2018-11-21
SG10201913837TA (en) 2020-03-30
EP3402491B1 (en) 2021-12-22
CA3009063A1 (en) 2017-07-20
AU2017207736A1 (en) 2018-07-12
PT3402491T (pt) 2022-03-03
JP2019501655A (ja) 2019-01-24
SG11201805253SA (en) 2018-07-30
RS62939B1 (sr) 2022-03-31
LT3402491T (lt) 2022-02-25
HRP20220147T1 (hr) 2022-04-15
EP4019026A1 (en) 2022-06-29
IL260010A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
MX2018008514A (es) Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones cancerosas.
CL2019000979A1 (es) Composiciones y anticuerpos anti-lag-3.
ECSP17070399A (es) Anticuerpos contra icos
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
MX2022010623A (es) Terapias de combinacion que comprenden un receptor quimerico de antigeno cd19 para el cancer.
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
MD3209310T2 (ro) Compoziții care conțin tulpini bacteriene
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
CY1121806T1 (el) Ιμιδαζοπυραζινονες ως αναστολεις pde1
MX2019004500A (es) Terapia de combinación para la inhibición de componente de complemeto (c3).
BR112018008882A8 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
EA201991818A1 (ru) Лечение рака
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
MA40364A (fr) Polythérapie pour le traitement du cancer
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CO2017010808A2 (es) Sistemas y métodos para la vigilancia activa del cancer de próstata
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas